FKBP13 Antibody is a monoclonal or polyclonal antibody raised against recombinant human FKBP13 (Ala22-Leu142), targeting the protein’s specific epitopes. Key features include:
Key Note: The antibody detects endogenous FKBP13 in lysates of human (e.g., MCF-7 breast cancer cells), rat (PC-12 adrenal pheochromocytoma cells), and mouse (Neuro-2A neuroblastoma cells) models .
FKBP13 Antibody is employed to study FKBP13’s involvement in cellular stress responses and disease mechanisms.
FKBP13 interacts with immunoglobulins (Igs) and facilitates their ubiquitination, directing misfolded proteins to ER-associated degradation (ERAD) . This process reduces ER stress in plasma cells, enabling their survival at the expense of antibody secretion . The antibody has been used to validate:
FKBP13-Ig interaction: Co-immunoprecipitation assays confirm physical binding between FKBP13 and IgA in plasmacytoma cells .
ER stress modulation: FKBP13 overexpression lowers XBP1-driven luciferase activity (a marker of ER stress) .
FKBP13’s upregulation in lung fibrosis and autoimmune conditions highlights its role in disease pathology:
Biomarker potential: FKBP13 levels correlate with disease severity in idiopathic pulmonary fibrosis (IPF) and autoimmune lung diseases .
Mechanistic insights: FKBP13-deficient mice exhibit exacerbated inflammation and fibrosis in bleomycin-induced lung injury models .
The antibody’s specificity is demonstrated through Western blot detection in diverse cell lines:
Secondary Antibodies: HRP-conjugated anti-rat IgG (for MAB4356) or anti-sheep IgG (for AF4356) .
Storage: -20°C to -70°C; avoid repeated freeze-thaw cycles .
Cross-reactivity: No reactivity with FKBP12, ensuring specificity .
Applications: Primarily validated for Western blot; further testing required for immunohistochemistry (IHC) or ELISA .
FKBP13 is a marker of long-lived plasma cells (LLPCs) in autoimmune mice. Its inverse correlation with secreted antibody levels suggests a trade-off between survival and Ig production . The antibody aids in studying this balance in models of autoimmunity.
While FKBP13 itself is unlikely to be a therapeutic target (due to its cytoprotective role), its detection via antibody-based methods could inform biomarker development for monitoring ER stress in diseases like IPF .